The S&P 500 soared more than 32% in 2013, and several big pharma companies, namely Bristol-Myers Squibb (BMY -2.92%), AbbVie (ABBV -2.82%), Roche (RHHBY -0.35%), Johnson & Johnson (JNJ -1.83%), and AstraZeneca (AZN -3.49%) also performed extraordinarily well. The following slideshow reveals why these companies beat out their big pharma peers and what drove their strong performances in 2013.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The pharmaceutical sector had a stellar 2013, but which stocks were the best?
Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences, ImmunoGen, and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Johnson & Johnson
JNJ
$152.38
(-1.83%)
$-2.84
Bristol Myers Squibb
BMY
$47.24
(-2.92%)
$-1.42
Roche Holding AG
RHHBY
$40.02
(-0.35%)
$0.14
AstraZeneca Plc
AZN
$70.98
(-3.49%)
$-2.57
AbbVie
ABBV
$185.48
(-2.82%)
$-5.38
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why Verve Therapeutics Stock Is Skyrocketing Today
Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
Why I Just Bought More of This Beaten-Down 7%-Yielding Dividend Stock
Why Novo Nordisk Stock Sank by Nearly 4% Today
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.